ArticleBreast cancer research : BCR2024

Correction: a phase 1b study of zilovertamab in combination with paclitaxel for locally advanced/unresectable or metastatic HER2-negative breast cancer.

Rebecca A Shatsky et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.